Increase in blood plasma levels of boron and strontium in hemodialyzed patients

Mauras, Y.; Ang, K.S.; Simon, Pierre; Tessier, Benoit; Cartier, F; Allain, Pierre

doi:10.1016/0009-8981(86)90074-4

Cited by 33 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar concentrations of boron (µg/mL) were reported in the plasma of humans (0.017-0.191) (Ferrando et al 1993;Hunt et al 1997;Iyengar et al 1990;Mauras et al 1986;Usuda et al 1997;Wallace et al 2002;Ward 1993), rats (0.038-0.039) (Seaborn and Nielsen 1994;Vaziri et al 2001), chicks (0.047-0.152) (Hunt 1989;Hunt 1996), cows (0.052-0.153) (Hunt 1996;Small et al 1997), lambs (0.163) (Hunt 1996), pigs (0.126) (Hunt 1996), and horses (0.227) (Hunt 1996). Liver boron concentrations (µg/g; dry weight) are similar in humans (1.1-5.4) (Shuler et al 1990;Ward 1987), rats (0.51) , chicks (1.01-4.4) (Rossi et al 1993), and cows (3.3) (Ward 1987); for brain tissue (µg/g; dry weight), similar in humans (0.87) (Shuler et al 1990), rats (0.64) , and chicks (1.01-1.05); for bone tissue (µg/g; dry weight), similar in humans (1.6) (Ward 1993), rats (1.3) , chicks (0.59-0.64) Hunt et al 1994;Wilson and Ruszler 1996), and mule deer (1.7) (Stelter 1980).…”

Section: Boron Concentrations In Healthy Tissuessupporting

confidence: 78%

Dietary Boron: Evidence for Essentiality and Homeostatic Control in Humans and Animals

Hunt

2007

Advances in Plant and Animal Boron Nutrition

View full text Add to dashboard Cite

Section: Boron Concentrations In Healthy Tissuessupporting

confidence: 78%

Dietary Boron: Evidence for Essentiality and Homeostatic Control in Humans and Animals

Hunt

2007

Advances in Plant and Animal Boron Nutrition

View full text Add to dashboard Cite

“…After DXA measurements and mechanical testing, bone samples (L 4 body and total femur) were assayed for Sr and Ca content as previously described by Mauras et al (29) Briefly, samples were dehydrated and reduced to ashes that were weighed and dissolved in 65% nitric acid (Prolabo). Solutions were diluted, and Sr and Ca were determined by inductively coupled plasma optical emission spectrometry (ICP‐OES) on a JY 24 spectrometer (Jobin‐Yvon, Longjumeau, France) fitted with a holographic grating of 3600 lines/mm.…”

Section: Methodsmentioning

confidence: 99%

“…All samples from control and treated animals were analyzed in the same run. Sr was assayed in rat plasma by an ICP‐OES method (29) . The ICP spectrometer was a JY 24 (Jobin‐Yvon) fitted with an holographic grating of 3600 lines/mm.…”

Section: Methodsmentioning

confidence: 99%

Strontium Ranelate Improves Bone Resistance by Increasing Bone Mass and Improving Architecture in Intact Female Rats

Ammann

Shen²,

Robin

et al. 2004

Journal of Bone and Mineral Research

238

174

View full text Add to dashboard Cite

Strontium ranelate given to intact rats at doses up to 900 mg/kg/day increases bone resistance, cortical and trabecular bone volume, micro-architecture, bone mass, and total ALP activity, thus indicating a bone-forming activity and an improvement of overall bone tissue quality.Introduction: Various anti-osteoporotic agents are available for clinical use; however, there is still a need for drugs able to positively influence the coupling between bone formation and bone resorption to increase bone mass and bone strength. Strontium ranelate (PROTELOS), a new chemical entity containing stable strontium (Sr), was tested for its capacity to influence bone quality and quantity. Materials and Methods: The long-term effects of strontium ranelate on bone were investigated in intact female rats treated with various doses of strontium ranelate (0, 225, 450, and 900 mg/kg/day) for 2 years. In a second series of experiments, the effects of 625 mg/kg/day were evaluated in intact male and female rats for the same period of time. Bone mineral mass and mechanical properties were evaluated at various skeletal sites (vertebra and femur), and bone tissue micro-architecture was evaluated by static histomorphometry at the tibio-fibular junction (cortical bone) and at the tibia metaphysis (trabecular bone). Plasma total alkaline phosphatase (ALP) activity and serum levels of insulin-like growth factor-I (IGF-I) were also assessed. Results: In female rats treated with strontium ranelate over 2 years, dose-dependent increases of bone strength and bone mass of the vertebral body (containing a large proportion of trabecular bone) and of the midshaft femur (containing mainly cortical bone) were detected without change in bone stiffness. Similar effects were observed in males at the level of the vertebra. This increase in mechanical properties was associated with improvements of the micro-architecture as assessed by increases of trabecular and cortical bone volumes and trabecular number and thickness. Finally, plasma total ALP activity and IGF-I were also increased in treated animals, compatible with a bone-forming activity of strontium ranelate. Conclusion: A long-term treatment with strontium ranelate in intact rats is very safe for bone and improves bone resistance by increasing bone mass and improving architecture while maintaining bone stiffness.

show abstract

“…(5) In uremic patients, either treated or not by hemodialysis, data in general point toward increased serum strontium levels as compared with subjects with normal renal function. (28,29) Recent preliminary findings of our group indicate that serum strontium levels in dialysis patients may differ greatly from center to center, ranging from values comparable to those noted in subjects with normal renal function (14 ± 7 g/l) up to 30-fold higher, i.e., mean ± SD of 29 ± 11 g/l, in the center with the lowest strontium concentrations, as compared with 466 ± 90 g/l in the center with the highest levels. Although evidence still has to be presented, this wide concentration range most likely is due to differences in the dialysate strontium concentration and perhaps variations in the dietary intake.…”

Section: Tissue Distributionmentioning

confidence: 99%